Clinical Trial Update: Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib as adjuvant therapy after surgery in patients with EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer Stage III | Phase 2 | Status: UNKNOWN